

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EC Healthcare
醫思健康

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2138)

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board (the “**Board**”) of directors (“**Directors**”) of EC Healthcare (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Ms. Wong Ka Ki Ada (“**Ms. Wong**”) has been appointed as executive Director, Chief Strategy Officer and Chief Investment Officer with effect from 11 October 2021.

The biographical details of Ms. Wong are set out as follow:

Ms. Wong, aged 40, has been the chief executive officer and an executive director of Eagle Asset Management (CP) Limited (the “**Champion REIT Manager**”), the manager of Champion REIT (Hong Kong stock code: 2778) since 2016. She is responsible for planning the strategic development of Champion REIT and ensuring that Champion REIT is operated in accordance with the stated investment strategy, policies and regulations. She also oversees the day-to-day operations. Ms Wong joined the Champion REIT Manager as deputy chief executive officer in 2014. She was also appointed as the chief investment officer of the Champion REIT Manager in 2015 and is responsible for identifying and evaluating potential acquisitions or investments opportunities. She is also responsible for the capital structure of Champion REIT, including the planning and overseeing of capital raising activities from the market. Ms Wong is a Responsible Officer as defined under the Securities and Futures Ordinance. She is also a director of all special purpose vehicles of Champion REIT.

Ms. Wong has almost 20 years of finance industry experience. Prior to joining the Champion REIT Manager, Ms. Wong worked at Citigroup and J.P. Morgan’s investment banking division to offer strategic advices to a number of blue chip corporates and Hong Kong real estate companies. She has also executed numbers of landmark IPOs, capital markets fund-raisings and strategic M&A transactions.

Ms. Wong graduated from University of Michigan (Ann Arbor) - Ross School of Business with a Bachelor of Business Administration degree. She was honoured with the titles of Best CEO in The

Asset 2020 Corporate ESG Award, Best CEO by FinanceAsia in 2020; Best IR by CEO by the Hong Kong Investor Relations Association from 2017 to 2020; and Asia's Best CEO by Corporate Governance Asia from 2017 to 2020. She is the Chairperson of Asia Pacific Real Assets Association HK chapter and a Fellow member of Royal Institution of Chartered Surveyors and Fellow member of The Hong Kong Institute of Directors.

Ms. Wong has entered into a director service agreement with the Company for a term of 3 years commencing on 11 October 2021. She is also subject to retirement by rotation and re-election at the general meeting of the Company in accordance with the articles of association of the Company. Pursuant to the director service agreement, Ms. Wong is entitled to, as executive Director, receive a remuneration of HK\$240,000 per annum plus other discretionary bonus and share options as may be determined by the Board. Further, Ms. Wong is entitled to, as Chief Strategy Officer and Chief Investment Officer, receive a remuneration of HK\$7,760,000 per annum (i.e. together with the remuneration of executive Director, HK\$8,000,000 per annum in total). Her remuneration package is determined by the Board based on the recommendation of the remuneration committee of the Company, taking into account the salaries paid by comparable companies, time commitment, duties and responsibilities of Ms. Wong, the Company's performance and profitability, remuneration policy and prevailing market rate.

As at the date of this announcement, Ms. Wong does not have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Save as disclosed above, Ms. Wong does not (i) hold any other position with the Company or any other members of the Group; (ii) have any relationships with any Directors, senior management or substantial or controlling shareholders of the Company (each as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")); (iii) has not held any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; and (iv) have other major appointments and professional qualifications.

Save as disclosed above, the Board is not aware of any other information to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules, nor are there any other matters concerning the appointment of Ms. Wong as executive Director, Chief Strategy Officer and Chief Investment Officer that need to be brought to the attention of the holders of securities of the Company.

The Board would like to take this opportunity to extend a warm welcome to Ms. Wong for joining the Group.

By Order of the Board
EC Healthcare
Raymond Siu
Company Secretary

Hong Kong, 13 September 2021

As at the date of this announcement, the executive Directors are Tang Chi Fai, Lee Gabriel, Lee Heung Wing, Wong Chi Cheung and Lu Lyn Wade Leslie; the non-executive Director is Luk Kun Shing Ben; and the independent non-executive Directors are Ma Ching Nam, Look Andrew, Lam Chi Hang Josekin.